Clarus Therapeutics Holdings Inc CRXT shares are trading lower by 52.82% at $0.85 after the company announced an upsized $30 million underwritten public offering at $1.10 per share.
The offering is expected to close on April 27, 2022, subject to customary closing conditions. Clarus expects to use the net proceeds from the offering, together with its existing cash, for working capital and other general corporate purposes.
See Also: Why Axsome Therapeutics Stock Is Falling Today
Clarus Therapeutics focuses on the development and commercialization of oral testosterone replacement therapy in the United States.
According to data from Benzinga Pro, Clarus Therapeutics has a 52-week high of $31.24 and a 52-week low of $0.61.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
